Treatment with Heberprot-P® in Amputation Stumps Complicated by Surgical Dehiscence

Abstract

Introduction: Amputation is a long-established surgical procedure and has been a health problem associated with a high incidence of complications; the number of amputees has increased annually. Heberprot-P^® was developed to promote the healing of severe ulcers in the lower extremities.

Objective: To characterize the patients who received Heberprot-P^® for major amputation stumps at the Department of Angiology and Vascular Surgery at Dr. Antonio Luaces Iraola Provincial Hospital in Ciego de Ávila.

Methods: A descriptive observational study was conducted over a three-year period. The study included 17 patients with lower-limb amputation stumps complicated by suture dehiscence who presented to the department and met the inclusion criteria. Age, sex, risk factors, indication for major amputation, and number of Heberprot‑P^® doses were recorded.

Results: The sample was predominantly male (82.3%), and 58% were between their sixth and seventh decades of life. Smoking was the predominant risk factor (76.4%). The primary indication for major amputation was stage IV obliterative atherosclerosis (57.1%). Sixty-four point seven percent of patients achieved 80% granulation between six and nine doses of Heberprot‑P^®.

Conclusions: The use of Heberprot‑P^® in treating skin complications of lower limb amputation stumps showed a high rate of healing, achieving 80% granulation in the first 6-9 sessions in most cases.